Xtampza Capsule, Extended Release
Product Images NDC 24510-120

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Xtampza (NDC 24510-120). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Collegium Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Xtampza 01)

A line graph depicting the percentage of subjects versus the percent reduction in drug liking. The y-axis represents the percentage of subjects from 0% to 100%, and the x-axis shows percent reduction in drug liking ranging from greater than 0% to 100%. The graph shows a decreasing trend in the percentage of subjects as the percent reduction in drug liking increases.*

FDA Label Image

Chemical Structure (Xtampza 02)

Chemical structure of oxycodone, the active ingredient in XTAMPZA ER extended-release capsules. The diagram shows the molecular arrangement of atoms and bonds characteristic of oxycodone.*

FDA Label Image

Figure 2 (Xtampza 03)

A line graph comparing the proportion of subjects achieving various percentage reductions in pain between XTAMPZA ER and placebo. The x-axis shows increasing thresholds of pain reduction from 10% to 100%, and the y-axis indicates the proportion of subjects. XTAMPZA ER is represented by a solid blue line, and placebo by a dashed red line.*

FDA Label Image

Figure 1 (Xtampza 04)

An instructional illustration showing hands opening a capsule and emptying the extended-release beads onto a surface or into a container. This image relates to XTAMPZA ER (Oxycodone) extended-release capsules designed for oral use.*

FDA Label Image

Figure 2 (Xtampza 05)

An instructional illustration showing a person placing an extended-release capsule into their mouth using their hand. The capsule is partially visible, and the perspective is side-on, focusing on the oral administration of the capsule.*

FDA Label Image

Figure 3 (Xtampza 06)

An instructional illustration showing a person lifting the cap off a child-resistant medication bottle, demonstrating how to open the container safely.*

FDA Label Image

Figure 4 (Xtampza 07)

An instructional illustration showing a hand placing capsules into a microwave oven. This image likely demonstrates a step related to the use or handling of the XTAMPZA ER extended-release oxycodone capsules.*

FDA Label Image

Principal Display Panel (9 mg Capsule Bottle Label)

Label for XTAMPZA ER 9 mg extended-release capsules containing oxycodone, manufactured by Collegium Pharmaceutical, Inc., with dosage details and dispensing instructions. The label indicates 100 capsules per container and includes a warning about taking the medication with food. Manufactured by Pateon Pharmaceuticals Inc., Cincinnati, OH.*

FDA Label Image

Principal Display Panel (13.5 mg Capsule Bottle Label)

Packaging label for XTAMPZA ER 13.5 mg extended-release capsules containing oxycodone. The label displays dosage strength, quantity of 100 capsules, and states prescription use only. It includes a warning to take with food and directions regarding dispensing conditions. Manufactured by Patheon Pharmaceuticals Inc. and labeled by Collegium Pharmaceutical, Inc.*

FDA Label Image

Principal Display Panel (18 mg Capsule Bottle Label)

Label for XTAMPZA ER 18 mg extended-release oral capsules, containing oxycodone. The label indicates each capsule contains 18 mg oxycodone, equivalent to 20 mg oxycodone hydrochloride. The package holds 100 capsules and is labeled Rx only. It displays warnings for taking with food to avoid decreased drug absorption and notes it is manufactured by Patheon Pharmaceuticals Inc. in Cincinnati, OH, with dispensing instructions.*

FDA Label Image

Principal Display Panel (27 mg Capsule Bottle Label)

Label for XTAMPTZA ER 27 mg extended-release oxycodone capsules from Collegium Pharmaceutical, Inc. The label states each capsule contains 27 mg oxycodone (equivalent to 30 mg oxycodone hydrochloride), with a package size of 100 capsules. It includes a usage note to always take with food, a storage temperature range of 15-30°C, and manufacturer information for Patheon Pharmaceuticals Inc., Cincinnati, OH. The label also features a barcode and handling instructions.*

FDA Label Image

Principal Display Panel (36 mg Capsule Bottle Label)

Label for XTAMPZA ER extended-release capsules containing oxycodone 36 mg. The label indicates each capsule contains 36 mg oxycodone (equivalent to 40 mg oxycodone hydrochloride) in a package of 100 capsules. It includes usage instructions, storage conditions, manufacturer information (Patheon Pharmaceuticals Inc.), and a warning to take with food to avoid decreased drug absorption. The product is distributed by Collegium Pharmaceutical, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.